Item 2.02. Results of Operations and Financial Conditions. On March 6, 2025, Arcturus Therapeutics Holdings Inc. (the “ Company” or “ Arcturus”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter and year ended December 31, 2024 and providing a corporate update (the “ Press Release”). The information contained in Item 2.02 of this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission (the “ SEC”), except as shall be expressly set forth by specific reference in any such filing. Cautionary Note Regarding Forward-Looking Statements

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated March 6, 2025 ───────────────────────────────────────────────────────────────────────────────── 104 Cover Page to this Current Report on Form 8-K in Inline XBRL SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 6, 2025 Arcturus Therapeutics Holdings Inc. ───────────────────────────────────────────────────────────────────────────────────────────── By: /s/ Joseph E. Payne Name: Joseph E. Payne Title: Chief Executive Officer